ICD-10 Coding for Neuroendocrine Carcinoid Tumor of Lung(C7A.090, C7A.1, D3A.090)
Complete ICD-10-CM coding and documentation guide for Neuroendocrine Carcinoid Tumor of Lung. Includes clinical validation requirements, documentation requirements, and coding pitfalls.
Also known as:
Related ICD-10 Code Ranges
Complete code families applicable to Neuroendocrine Carcinoid Tumor of Lung
C7A.0-C7A.8Primary Range
Malignant neuroendocrine tumors
This range includes codes for malignant neuroendocrine tumors, including carcinoid tumors of the lung.
Benign neuroendocrine tumors
This range includes codes for benign neuroendocrine tumors, which are less common in the lung.
Code Comparison: When to Use Each Code
Compare key differences between these codes to ensure accurate selection
| Code | Description | When to Use | Key Documentation |
|---|---|---|---|
| C7A.090 | Malignant carcinoid tumor of bronchus and lung | Use for malignant carcinoid tumors of the lung, confirmed by pathology. |
|
| C7A.1 | Malignant poorly differentiated neuroendocrine tumors | Use for poorly differentiated neuroendocrine carcinomas of the lung. |
|
| D3A.090 | Benign carcinoid tumor of bronchus and lung | Use for benign carcinoid tumors of the lung, confirmed by pathology. |
|
Clinical Decision Support
Always review the patient's clinical documentation thoroughly. When in doubt, choose the more specific code and ensure documentation supports it.
Key Information: ICD-10 code for neuroendocrine carcinoid tumor of lung
Essential facts and insights about Neuroendocrine Carcinoid Tumor of Lung
Primary ICD-10-CM Codes for neuroendocrine carcinoid cancer of lung
Decision Criteria
clinical Criteria
- Histologic confirmation of malignancy with typical or atypical carcinoid features.
Applicable To
- Typical carcinoid tumor
- Atypical carcinoid tumor
Excludes
- Benign carcinoid tumor (D3A.090)
Clinical Validation Requirements
- Mitotic count <10/2mm²
- No necrosis
- Histologic confirmation of malignancy
Code-Specific Risks
- Misclassification as benign
- Incorrect differentiation documentation
Coding Notes
- Ensure documentation specifies 'malignant' and includes mitotic count.
C7A.1 - Malignant poorly differentiated neuroendocrine tumors
Use for poorly differentiated neuroendocrine carcinomas of the lung.
Applicable To
- Large cell neuroendocrine carcinoma
Excludes
- Small cell lung cancer (C34.9)
Clinical Validation Requirements
- Mitotic count ≥10/2mm²
- Presence of necrosis
- Histologic confirmation of poor differentiation
Coding Notes
Ensure documentation specifies 'poorly differentiated' and includes mitotic count.
D3A.090 - Benign carcinoid tumor of bronchus and lung
Use for benign carcinoid tumors of the lung, confirmed by pathology.
Applicable To
- Benign carcinoid tumor
Excludes
- Malignant carcinoid tumor (C7A.090)
Clinical Validation Requirements
- Histologic confirmation of benign behavior
- Absence of invasion or metastasis
Coding Notes
Ensure documentation specifies 'benign' and confirms non-invasive behavior.
Ancillary Codes
Additional codes that should be used in conjunction with the main diagnosis codes when applicable.
Carcinoid syndrome
E34.0Differential Codes
Alternative codes to consider when ruling out similar conditions to the primary diagnosis.
Malignant neoplasm of unspecified part of bronchus or lung
C34.90Malignant neoplasm of bronchus and lung, unspecified
C34.9Malignant carcinoid tumor of bronchus and lung
C7A.090Documentation & Coding Risks
Avoid these common documentation and coding issues when documenting Neuroendocrine Carcinoid Tumor of Lung to ensure proper reimbursement, maintain compliance, and reduce audit risk. These guidelines are particularly important when using ICD-10 code C7A.090.
Impact
Clinical: Leads to incorrect diagnosis classification., Regulatory: Non-compliance with documentation standards., Financial: Potential loss of reimbursement due to incorrect coding.
Mitigation Strategy
Include differentiation status in all pathology reports, Educate staff on documentation standards
Impact
Reimbursement: Incorrect classification can lead to reduced reimbursement., Compliance: Non-compliance with coding guidelines., Data Quality: Inaccurate clinical data affecting patient records.
Mitigation Strategy
Verify histologic reports for malignancy indicators such as mitotic count and necrosis.
Impact
Incomplete documentation of tumor differentiation and mitotic count.
Mitigation Strategy
Implement standardized templates for pathology reports.
Documentation errors, coding pitfalls, and audit risks are interconnected aspects of medical coding and billing. Addressing all three areas helps ensure accurate coding, optimal reimbursement, and regulatory compliance.
Frequently Asked Questions
Common questions about ICD-10 coding for Neuroendocrine Carcinoid Tumor of Lung, with expert answers to help guide accurate code selection and documentation.
Documentation Templates for Neuroendocrine Carcinoid Tumor of Lung
Use these documentation templates to ensure complete and accurate documentation for Neuroendocrine Carcinoid Tumor of Lung. These templates include all required elements for proper coding and billing.
Pathology Report for Lung Carcinoid
Specialty: PathologyRequired Elements
- Histologic type
- Mitotic count
- Necrosis presence
- Differentiation status
Example Documentation
Examples: Poor vs. Good Documentation
Poor Documentation Example
Good Documentation Example
Explanation
Need help with ICD-10 coding for Neuroendocrine Carcinoid Tumor of Lung? Ask your questions below.